AirNexis Therapeutics

Executive Summary

AirNexis Therapeutics is a private, clinical-stage biotech company headquartered in Boston, Massachusetts, dedicated to developing innovative small molecule therapies for respiratory diseases. Founded in 2020, the company is advancing its lead candidate, AN01, a dual PDE3/4 inhibitor currently in Phase 2 clinical trials for Chronic Obstructive Pulmonary Disease (COPD). COPD represents a significant unmet medical need, with limited treatment options that address both inflammation and bronchodilation. AN01’s dual mechanism targets both pathways, potentially offering improved efficacy and safety over existing therapies. The company operates in a competitive landscape but leverages a differentiated approach in the PDE3/4 inhibitor space, which has shown promise in earlier studies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data Readout for AN01 in COPD50% success
• H2 2026Potential Partnership or Licensing Deal for AN0130% success